Abstract
Canakinumab (Ilaris®, Novartis) is a human IgG1k monoclonal anti-human antibody, which selectively binds to interleukin-1β (IL-1β) and neutralizes it.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Canakinumab (Ilaris®). BLA 125319 Medical Review. FDA 2009
Ilaris® (canakinumab). Summary basis of decision (SBD). Health Canada 2010
Canakinumab (Ilaris®). EMA WC500031680 Annex I, 2011
Ilaris® (canakinumab). Prescribing Information. Novartis 2012
Dhimolea E (2010) Canakinumab. MAbs 2:1–13
Curran MP (2012) Canakinumab in patients with cryopyrin-associated periodic syndrome. Biodrugs 26(53):59
Stylianou E and Saklatvala J (1008) Interleukin-1 Int J Biochem 30:1075–1079
Dubois EA, Rissmann R, Cohen AF (2011) Rilonacept and Canakinumab. BJCP 71:639–641
Chakraborty A, Tannenbaum S, Rordorf C et al (2012) Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibody. Clin Pharmacokinet 51:1–18
Kuemmerle-Deschner JB, Hachulla E, Cartwright R et al (2011) Two-year results from an open label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann Rheum Dis 70:2095–2102
Alten R, Gomez-Reino J, Durez P et al (2011) (2011) Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding result. BMC Musculoskeletal Disorders 12:153–163
Ruperto N, Quartier P, Wulffraat N et al (2012) A phase II, multicenter, open-label study and preliminary safety and efficacy of canakinumab in Systemic Juvenile Idiopathic Arthritis with active systemic features. Arthritis Rheum 64:557–567
Arthritis Advisory Committee (AAC) FDA Briefing Document AAC-B1-01 UCM 259596 June 2011
Schlesinger N, Alten RE, Bardin T et al (2012) Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomized, multicentre, active-controlled, double blind trials and their initial extensions. Ann Rheum Dis (2012). doi:10.1136/annrheumdis-2011-200908
Uguriu S, Ucar D, Seyahi E et al (2012) Canakinumab in a patient with juvenile Behçet’s syndrome with refractory eye disease. Ann Rheum Dis 71:1589–1591
De Koning HD, Schalkwijk J, van der Ven-Jongekrijg J et al (2012) Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler’s syndrome. Ann Rheum Dis. doi:10.1136/annrheumdis-2012-202192
Wittkowski H, Kuemmerle-Deschner JB, Austermann J et al (2011) MRP8 and MRP14, phagocyte-specific danger signals, are sensitive biomarkers of disease activity in cryopyrin-associated periodic syndromes. Ann Rheum Dis 70:2075–2081
Author information
Authors and Affiliations
Corresponding author
1 Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
Copyright information
© 2014 Springer-Verlag Italia
About this chapter
Cite this chapter
Tridente, G. (2014). Canakinumab. In: Adverse Events with Biomedicines. Springer, Milano. https://doi.org/10.1007/978-88-470-5313-7_12
Download citation
DOI: https://doi.org/10.1007/978-88-470-5313-7_12
Published:
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-5312-0
Online ISBN: 978-88-470-5313-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)